• 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>Cephalon将收购瑞士制药商Mepha

    江苏福彩快三开奖结果: Cephalon将收购瑞士制药商Mepha

    Cephalon2010年5月3日 10:21 点击:2566

    时时彩网络平台 www.qlgr.net 美国Cephalon Inc
    Cephalon Inc(CEPH)宣布,已签署一项协议,将以5.90亿美元的价格收购总部位于瑞士的制药商Mepha AG及其子公司。

      这家总部位于宾夕法尼亚州Frazer的公司表示,此项收购将使其国际业务的规模扩大一倍,并将推动其在欧洲、中东以及非洲市场的未来增长。此项交易还将使该公司能够为全部三类药品市场提供服务,包括专有品牌药物、仿制药及品牌仿制药市场。

      Cephalon董事长兼首席执行官弗兰克·巴尔迪诺(Frank Baldino)在一份声明中表示:“我们认为这一均势将推动增长,并稳定我们的业务。”

      Cephalon预计此项收购将对其2010财年调整后每股盈利起到推动作用。

      在获得监管批准,以及扫清其它多个障碍之后,此项交易预计将于未来10到12周内完成。

      德银证券公司将在此项交易中担任Cephalon的独家财务顾问。

     
    更新
    2010年4月10日,生物技术公司Cephalon Inc(CEPH)宣布,已完成了对瑞士制药商Mepha价值大约6.15亿美元的收购。

      这家总部位于宾夕法尼亚州Frazer的公司表示,Mepha现已成为Cephalon的一家全资子公司,并且表示,此举将扩大Cephalon在欧洲市场的存在。

      Cephalon欧洲部门执行副总裁阿伦·阿莱格斯(Alain Aragues)在一份声明中表示:“Mepha是瑞士第一大仿制药公司,在其它很多市场也声名赫赫,Cephalon计划充分利用其品牌知名度。”

      Cephalon已表示,此项交易将使其国际业务的规模扩大一倍,并为其在欧洲、中东和非洲市场的未来增长奠定基础。

      今年早些时候,Cephalon宣布将以5.90亿美元的价格收购Mepha,但周五表示,最终收购价格已被调整,并将接受更多的“收购后运营资本及净债务调整。”

    Cephalon新闻稿

    Cephalon Completes Acquisition of Swiss Pharmaceutical Company Mepha

    04/09/2010

     

    Acquisition Diversifies Global Pharmaceutical Business and Expands Presence in Western and Central Europe, Africa, and Middle East Territories

     

    FRAZER, Pa., AESCH, Switzerland and MAISONS-ALFORT, France, April 9, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.

    "We are proud to include Mepha as part of the Cephalon family. Mepha has a strong reputation for high quality products and services that deliver value to patients and healthcare professionals," said Frank Baldino, Jr., Ph.D., Chairman and CEO of Cephalon. "This acquisition expands our presence in Europe, and we believe Mepha will contribute to our long-term growth."

    Alain Aragues Executive Vice President and President of Cephalon Europe said, "We are pleased to add Mepha's experience and expertise, which are critical to our successful development of a balanced business mix in Europe, Middle East and Africa. Cephalon intends to leverage Mepha's brand recognition as the number one generics company in Switzerland and a prominent generic pharmaceutical company in many other markets."

    About Mepha

    Founded in 1949, Mepha is a Swiss-based innovative pharmaceutical company developing, manufacturing and marketing branded and non-branded generic products in more than 50 countries. Mepha manufactures many of its products in Aesch/Basel -- Switzerland, to a high Swiss-quality standard. Mepha's R & D organization has developed improved branded generics either through new formulations or using drug delivery technologies, providing additional benefits for healthcare professionals and patients. Furthermore, Mepha is actively involved in researching malaria treatments for adults and children.

    Mepha is the leading company in the Swiss generic market, with more than 120 products and it brings unique services to healthcare professionals and patients. Mepha has subsidiaries in Portugal and the Baltic States. Through partnerships, Mepha markets its products in other European countries, in the Middle East, Africa, South and Central America. For more information on Mepha, visit their website at //www.mepha.com/.

    About Cephalon, Inc.

    Cephalon is an international biopharmaceutical company dedicated to discovering, developing and bringing to market medications for difficult to treat and rare conditions. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients around the world in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide.

    Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Operational subsidiaries are located in the United Kingdom, France, Germany, Italy, Spain, the Netherlands (which covers the entire Benelux region), and Poland (which covers Eastern Europe and Scandinavia). Cephalon Europe markets more than 30 products in 50 countries in four therapeutic areas: central nervous system, pain, primary care and oncology.

    The company's proprietary products in the United States include: NUVIGIL(R) (armodafinil) Tablets [C-IV], TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), PROVIGIL(R) (modafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at //www.cephalon.com/ or by calling 1-800-896-5855.

    In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, future plans and prospects with respect to Mepha AG, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

    Contacts:

    US Media

    Sheryl Williams
    +1-610-738-6493
    [email protected]

    Investors

    Robert (Chip) Merritt
    +1-610-738-6376
    [email protected]

    European Media

    Marie-Dominique de La Salle
    + 33 (1) 49 81 82 48
    [email protected]

    Investors

    Linda Pavy
    Burson Marsteller
    + 33 (6) 07 59 43 95
    [email protected]

     

    SOURCE: Cephalon, Inc.

    (来源: Cephalon )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 世界足球国家队排名 时时彩后二定5个胆码技巧 云南快乐十分开奖今天 香港100%最准一尾中特 澳洲幸运5开奖最快 六肖中特准 开奖 加拿大快乐8开奖网址 七星彩开奖结果查询 竞彩2串1月入万元 网上兼职彩票 500元 倍投方案 稳赚 福彩25选7开奖时间 极速赛车的出号规律 24小时现金捕鱼注册送分 田伟足彩推荐今日